Hasebe F., Iwai S., Watanabe A. et al. Dietary supplement of mushrooms promotes SCFA production and moderately associates with IgA production: A pilot clinical study. Front Nutr. 2022;9:1078060.
Rationale
Mushrooms deliver fermentable β-glucans and fiber to the colon; the practical question is whether an ordinary dietary serving measurably shifts short-chain fatty acids (SCFAs) and gut immune markers in humans.
Methods
A parallel controlled clinical study: 80 healthy Japanese adults ate a daily mixed-mushroom serving (bunashimeji, shiitake, enokitake and others) or a control diet for 4 weeks. Fecal SCFAs (butyrate, propionate, others) and secretory IgA were measured.
Results
Butyrate (p=0.001) and propionate (p=0.020) rose significantly in the mushroom group. Fecal IgA showed only a weak increase overall (p=0.08) — but the IgA gain was stronger in participants whose SCFA levels were already high at baseline, indicating the response to mushrooms depends on the starting microbiota.
Conclusions
A realistic daily mushroom serving measurably increased beneficial SCFAs — evidence that culinary mushrooms function as a prebiotic substrate in humans. The IgA response is conditional on baseline microbiota.
Worth noting
The SCFA-by-baseline interaction is the scientifically interesting finding: same food, different microbiota, different response — the premise behind personalized nutrition. p=0.08 for IgA is a trend, not a result; honest cards keep it that way.